Cellular immunotherapy for malignant tumors has gradually achieved clinical efficacy and is considered to be one of the major approaches for the treatment of tumors. Key point 1: In autologous cell therapy, it is important to ensure a sufficient number of individual nucleated cells. Some patients have asked if it is possible to draw 50 ml of blood from a vein. I personally do not recommend this approach unless the patient has a condition that does not allow for the separation of blood from the machine. This is because the number of cells collected is directly related to the final number of culture expansions, and if this is combined with a short culture time, then the number is often insufficient and therefore clinical efficacy cannot be guaranteed; Key point 2: How many cycles do I need to do? Key point 3: Cellular immunotherapy requires a highly specialized team with experts who know and understand immunology, and its complexity is far more difficult than chemotherapy; Key point 4: It is not the case that the more types of cells are transfused, the better the efficacy. whether the immune function is corrected and restored;